Product/Composition:- | Glecaprevir/Pibrentasvir |
---|---|
Strength:- | Glecaprevir 100 mg Pibrentasvir 40 mg |
Form:- | Oral tablets |
Reference Brands:- | Mavyret®, |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Glecaprevir/Pibrentasvir, marketed as Mavyret®, is a fixed-dose oral antiviral used to treat chronic Hepatitis C (HCV) genotypes 1–6. Approved in the US and EU, it offers a short 8–12 week regimen for adults and children (≥3 years), with or without cirrhosis. Ideal for pharma B2B distribution.
Glecaprevir/Pibrentasvir is a fixed-dose, pan-genotypic antiviral combination used in the treatment of chronic Hepatitis C virus (HCV) infection across genotypes 1 through 6. Marketed as Mavyret® in the US and EU by AbbVie, it combines Glecaprevir, an NS3/4A protease inhibitor, and Pibrentasvir, an NS5A inhibitor, to deliver a highly effective once-daily oral regimen. Approved by the FDA and EMA, it is indicated for use in adults and pediatric patients (≥3 years), with or without cirrhosis. Glecaprevir/Pibrentasvir is widely used in pharma B2B for short-duration (typically 8–12 weeks) HCV treatment strategies across global markets.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications